-
Top Financial Tweets From February 11, 2014
Tuesday, February 11, 2014 - 11:56am | 470Read More...The wealth of information and opinions spread on Twitter has grown each and every year since its inception in 2006. Benzinga will try to collect some of the notable tweets from the business, media and financial markets as days go by. Some may be newsworthy, some may be humorous - all help...
-
Analysts Comment on Merck's Hep C Regiment Advances
Monday, November 4, 2013 - 11:39am | 252Read More...Several analysts commented on Merck's (NYSE: MRK)'s advances on Hepatitis C cure regiment. ISI analyst Mark Schoenebaum commented that Merck's oral regimen for hepatitis C genotype 1 may be the first "truly clinical competitive" regimen against Gilead. Schoenebaum noted that this one pill per day...
-
ISI Group Believes That Genzyme Corporation (GENZ) Could Jump to $80
Tuesday, July 27, 2010 - 7:43pm | 192Read More...Mark Schoenebaum of ISI Group said on CNBC's Fast Money that a rumor that Sanofi-Aventis SA (ADR) (NYSE: SNY) could buy Genzyme Corporation (NASDAQ: GENZ) makes a lot of sense. He explained that Genzyme (GENZ) is still run by its founding CEO. He is 66 years old, and the company has some...
-
ISI Group Is Bullish On AMLN, HGSI, GENZ And DNDN
Wednesday, July 14, 2010 - 7:13pm | 289Read More...Mark Schoenebaum of ISI Group said on CNBC's Fast Money that he is looking at biotech stocks that have a specific catalyst. He believes that Amylin Pharmaceuticals, Inc. (NASDAQ: AMLN) is a stock to watch, and sees it over $20 by the end of the year. Amylin has a diabetes drug that should be...
-
Deutsche Bank Analyst Likes Genzyme (GENZ), Gilead (GILD) And Amgen (AMGN)
Friday, September 11, 2009 - 6:26pm | 210Read More...Deutsche Bank analyst Mark Schoenebaum thinks that Genzyme (NASDAQ: GENZ), Gilead (NASDAQ: GILD) And Amgen (NASDAQ: AMGN) are currently undervalued. He thinks that Genzyme (GENZ) is the most controversial stock in all of biotech. They were forced to temporarily halt production of its plant due to...
